SecBot SecBot

TNYA

Tenaya Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001858848 Biotech & Drug Discovery
$0.4086 +0.02 (+5.04%)
Oct 26 4:00 PM ET · prev $0.3890
Market cap
$88.4M
Micro cap
Median target
$3.00
+634% · range $2.00–5.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.10
1 year
−75.4%
from $1.66 · Oct 27
30 days
−30.7%
from $0.5900
52-week range
$0.3780–1.66
−75% from high · low Oct 19
Avg volume 20D
3.98M
Oct 14 spike 18.15M
Short interest
22.92M
≈10.2% of shares · +5.9%
Days to cover
7.5
at average volume
Insider net
−$6.0M
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 2 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Tenaya Therapeutics is soliciting stockholder approval for a reverse stock split (ratio between 1-for-10 and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $6.0M.

  • InstitutionsBULLISH

    Q2 2026: 9 added (0 new), 6 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.099 → −$0.095 over 90 days. 0 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest +5.9% to 22.92M shares. 7.5 days to cover, ≈10.2% of shares.

  • TrendDOWNTREND

    32% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Sep 30.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPADD3,503,178$2.6M
Squarepoint Ops LLCADD659,247$487.2K
UBS Group AGTRIM456,555$337.4K
JANE STREET GROUP, LLCTRIM450,435$332.9K
GOLDMAN SACHS GROUP INCADD294,739$217.8K
CITIGROUP INCDOUBLED92,417$68.3K
Vanguard Personalized Indexing Management, LLCTRIM34,871$25.8K
ROYAL BANK OF CANADADOUBLED29,107$22.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 5 analysts

Price is below the lowest target. Median implies +634%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Mar 12, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Dec 18, 2025Canaccord Genuity
MAINTAIN
MAINTAINBuy
Dec 12, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Dec 12, 2025Chardan Capital
MAINTAIN
MAINTAINBuy
Nov 10, 2025Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 2, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$6.0M
sold · 4 insiders
DateInsiderTypeValue
Sep 10, 2026
Tingley Whittemore
Chief Medical Officer
AWARD49,000 sh
Sep 10, 2026
Tingley Whittemore
Chief Medical Officer
AWARD293,000 sh
Sep 10, 2026
Ali Faraz
Chief Executive Officer
AWARD122,000 sh
Sep 10, 2026
Ali Faraz
Chief Executive Officer
AWARD732,500 sh
Aug 17, 2026
Tingley Whittemore
Chief Medical Officer
SELL$1.2K
Aug 17, 2026
Tingley Whittemore
Chief Medical Officer
SELL$1.3K
Aug 17, 2026
Tingley Whittemore
Chief Medical Officer
SELL$1.6K
Aug 17, 2026
Ali Faraz
Chief Executive Officer
SELL$5.3K

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.10
EPS estimate, this quarter
+4%
estimate change, 90 days
0↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.10-$0.10–-$0.09+1.0%$800.0K
Next Q-$0.09-$0.10–-$0.08+3.6%$2.5M
Current FY-$0.42-$0.49–-$0.36+9.4%$4.0M
Next FY-$0.39-$0.47–-$0.35+5.3%$2.5M
Reddit
Recent posts
r/pennystocks Neutral 27d ago
Anyone else keeping an eye on these micro-cap charts? Sorting out my watchlists.
1 upvotes · 5 comments
All social signals and their track records

Short side

FINRA· Sep 30, 2026
22,922,426
shares short
+5.9%
vs prior settlement
7.5
days to cover
≈10.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Tenaya Therapeutics filed a DEFA14A soliciting stockholder approval for a reverse stock split at a ratio between…
DEFA14A — Impact 4/10
Oct 23, 2026 SEC
Tenaya Therapeutics is soliciting stockholder approval for a reverse stock split (ratio between 1-for-10 and 1-for-25)…
DEF 14A — Impact 6/10
Sep 10, 2026 Insider
Tingley Whittemore was granted 49,000 shares
Chief Medical Officer
Sep 10, 2026 Insider
Tingley Whittemore was granted 293,000 shares
Chief Medical Officer
Sep 10, 2026 Insider
Ali Faraz was granted 122,000 shares
Chief Executive Officer
Aug 17, 2026 SEC
Ali Faraz, an officer and director of Tenaya Therapeutics, filed a Form 144 notice of intent to sell 22,232 shares of…
144 — Impact 4/10
Aug 12, 2026 Earnings calendar
TNYA Q2 2026 Earnings Scheduled — 2026-08-12
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — ADD
3,503,178 shares ($2.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
TNYA Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 12, 2026
Earnings date
TNYA Q2 2026 Earnings Scheduled — 2026-08-12
Aug 3, 2026
Earnings date
TNYA Q2 2026 Earnings Scheduled — 2026-08-03
Jul 14, 2026
Press release
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with…
Jun 29, 2026
Press release
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of…
Jun 3, 2026
Press release
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM

SecBot reports

11 filings · 2 press releases · 1 bullish · 3 bearish · 7 neutral
All TNYA filing & press-release reports (13)